LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Inicio・Lista de Acciones・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Cerrado

SectorSanidad

17.37 1.28

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

17.09

Máximo

17.49

Métricas clave
By Trading Economics
Ingresos	-607K -51M
Ventas	-28M 100M
BPA	-0.46
Margen de beneficios	-51.215
Empleados	1,784
EBITDA	4.1M -44M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+88.7% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-541M 1.8B
Apertura anterior	16.09
Cierre anterior	17.37

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

87 / 344 Clasificación en Healthcare

Zai Lab Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 jun 2026, 21:51 UTC

Principales Movimientos del Mercado

Merlin Shares Rally After Defense Department's Design Review Wraps

4 jun 2026, 23:46 UTC

Charlas de Mercado

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 jun 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 jun 2026, 23:42 UTC

Adquisiciones, fusiones, absorciones

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 jun 2026, 23:41 UTC

Adquisiciones, fusiones, absorciones

Energy Resources of Australia to Enter Trading Halt

4 jun 2026, 23:34 UTC

Charlas de Mercado

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 jun 2026, 23:31 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 jun 2026, 23:31 UTC

Charlas de Mercado

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 jun 2026, 23:31 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

4 jun 2026, 23:08 UTC

Charlas de Mercado

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 jun 2026, 22:41 UTC

Charlas de Mercado

Australia Shares Set to Rise at the Open -- Market Talk

4 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

4 jun 2026, 20:44 UTC

Adquisiciones, fusiones, absorciones

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 jun 2026, 20:16 UTC

Charlas de Mercado

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 jun 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 jun 2026, 19:46 UTC

Charlas de Mercado

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 jun 2026, 19:38 UTC

Charlas de Mercado

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 jun 2026, 19:30 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 jun 2026, 18:47 UTC

Adquisiciones, fusiones, absorciones

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 jun 2026, 18:38 UTC

Ganancias

Money Quote: Tech Weakness in Context -- WSJ

4 jun 2026, 18:24 UTC

Ganancias

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 17:09 UTC

Charlas de Mercado

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 jun 2026, 16:58 UTC

Ganancias

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 16:46 UTC

Charlas de Mercado

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 jun 2026, 16:38 UTC

Ganancias

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 jun 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

4 jun 2026, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

4 jun 2026, 16:13 UTC

Charlas de Mercado

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 jun 2026, 16:11 UTC

Charlas de Mercado

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 jun 2026, 15:56 UTC

Charlas de Mercado

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparación entre iguales

Cambio de precio

Zai Lab Ltd ADR previsión

Precio Objetivo

By TipRanks

88.7% repunte

Estimación a 12 Meses

Media 32.4 USD 88.7%

Máximo 44 USD

Mínimo 21.6 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Zai Lab Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Zai Lab Ltd ADR Dist en los últimos 3 meses.

Sentimiento

By Acuity

87 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.